Cargando…
Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures)....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528284/ https://www.ncbi.nlm.nih.gov/pubmed/31113420 http://dx.doi.org/10.1186/s12906-019-2517-5 |
_version_ | 1783420183393599488 |
---|---|
author | Felenda, Jennifer E. Turek, Claudia Mörbt, Nora Herrick, Anja Müller, Margit B. Stintzing, Florian C. |
author_facet | Felenda, Jennifer E. Turek, Claudia Mörbt, Nora Herrick, Anja Müller, Margit B. Stintzing, Florian C. |
author_sort | Felenda, Jennifer E. |
collection | PubMed |
description | BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures). Therefore, in vitro investigations were performed on safety aspects of a Helleborus niger aqueous fermented extract (HNE). In addition its therapeutic potential against various cancer cell lines was assessed to gain insight into the respective mechanisms of action. METHODS: To evaluate the safe use of HNE, Ames and hemolytic tests were carried out. Two angiogenesis assays in 2D and 3D design were conducted to assess the anti-angiogenetic potential, for which human umbilical vein endothelial cells (HUVEC) were chosen. A panel of tumor cell lines was used in 2D and 3D proliferation assays as well in the migration- and invasion-assay. All investigations were performed with HNE compared to reference substances. The 2D proliferation assay was additionally performed with isolated compounds of HNE (characteristic steroidal saponins). RESULTS: HNE did not exhibit any genotoxic potential. Concentrations up to 10 μl/ml were classified as non-hemolytic. HNE exerted anti-angiogenetic effects in HUVEC and anti-proliferative effects in five cancer cell lines, whereas hellebosaponin A and D as well macranthosid I did not show comparable effects neither singly nor in combination. Due to the inherent instability of protoanemonin in isolated form, parallel investigations with protoanemonin could not be performed. HNE (600–1000 μg/ml) inhibited the migration of certain cancer cells by > 80% such as Caki-2, DLD-1 and SK-N-SH. CONCLUSION: HNE exhibit neither genotoxic nor hemolytic potential. The present investigations verify the anti-angiogenetic effects on HUVEC, the anti-proliferative effects and migration-inhibiting properties on tumor cells. The lower effect of the relevant steroidal saponins compared to the whole extract underlines the fact that the latter is more effective than a blend of isolated pharmacologically active components. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12906-019-2517-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6528284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65282842019-05-28 Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment Felenda, Jennifer E. Turek, Claudia Mörbt, Nora Herrick, Anja Müller, Margit B. Stintzing, Florian C. BMC Complement Altern Med Research Article BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures). Therefore, in vitro investigations were performed on safety aspects of a Helleborus niger aqueous fermented extract (HNE). In addition its therapeutic potential against various cancer cell lines was assessed to gain insight into the respective mechanisms of action. METHODS: To evaluate the safe use of HNE, Ames and hemolytic tests were carried out. Two angiogenesis assays in 2D and 3D design were conducted to assess the anti-angiogenetic potential, for which human umbilical vein endothelial cells (HUVEC) were chosen. A panel of tumor cell lines was used in 2D and 3D proliferation assays as well in the migration- and invasion-assay. All investigations were performed with HNE compared to reference substances. The 2D proliferation assay was additionally performed with isolated compounds of HNE (characteristic steroidal saponins). RESULTS: HNE did not exhibit any genotoxic potential. Concentrations up to 10 μl/ml were classified as non-hemolytic. HNE exerted anti-angiogenetic effects in HUVEC and anti-proliferative effects in five cancer cell lines, whereas hellebosaponin A and D as well macranthosid I did not show comparable effects neither singly nor in combination. Due to the inherent instability of protoanemonin in isolated form, parallel investigations with protoanemonin could not be performed. HNE (600–1000 μg/ml) inhibited the migration of certain cancer cells by > 80% such as Caki-2, DLD-1 and SK-N-SH. CONCLUSION: HNE exhibit neither genotoxic nor hemolytic potential. The present investigations verify the anti-angiogenetic effects on HUVEC, the anti-proliferative effects and migration-inhibiting properties on tumor cells. The lower effect of the relevant steroidal saponins compared to the whole extract underlines the fact that the latter is more effective than a blend of isolated pharmacologically active components. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12906-019-2517-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-21 /pmc/articles/PMC6528284/ /pubmed/31113420 http://dx.doi.org/10.1186/s12906-019-2517-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Felenda, Jennifer E. Turek, Claudia Mörbt, Nora Herrick, Anja Müller, Margit B. Stintzing, Florian C. Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title | Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title_full | Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title_fullStr | Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title_full_unstemmed | Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title_short | Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
title_sort | preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528284/ https://www.ncbi.nlm.nih.gov/pubmed/31113420 http://dx.doi.org/10.1186/s12906-019-2517-5 |
work_keys_str_mv | AT felendajennifere preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment AT turekclaudia preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment AT morbtnora preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment AT herrickanja preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment AT mullermargitb preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment AT stintzingflorianc preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment |